dotMD.com
Join Community
📖Clinical Research Library Talk in Gut, Labs & Supplements Space 711+ Logs • Free →🧮Lab Calculator ↓
Reading this clinical breakthrough? See how real patients are applying these numbers in real life. Compare real-world patient outcomes, lab numbers, and doctor visit tips—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Gut, Labs & Supplements Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Gut, Labs & Supplements Space →
★ Breakthrough Medical Research • 15 Landmark Multi-Trial Guides • 6,280 Indexed Studies

Patient Literacy, FDA Pharmacokinetics & Generic Drug Quality — Clinical Trial Breakdowns & PubMed Evidence

Evidence-audited guides decoding FDA food-effect bioavailability studies ("Take With Food"), FDA Orange Book 80%–125% generic bioequivalence (3.5% mean AUC difference across 2,070 human studies), and AHRQ 15-minute doctor visit question checklists. Explore 188 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.

★ #1 Lead Breakthrough Study • NEJM SURMOUNT-1 (176 Weeks) N = 1,032 Adults • p < 0.001

Once-Weekly Tirzepatide Cuts Type 2 Diabetes Progression by 94% Over 3 Years—With a 22.9% Sustained Weight Reduction

The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).

Read the Full Breakthrough Breakdown → Jump to All 15 Landmark Breakthroughs ↓
Two biomedical scientists in white lab coats inside a sunlit medical research laboratory pipetting clinical assay samples and reviewing trial results
Inside the Clinical Evidence Lab: Our research desk audits 6,280 human trials from NEJM, The Lancet, JAMA, and NCBI PubMed—reporting true Absolute Risk Reduction (ARR) and sample sizes (N) without pharma spin.
Reset
3. All Indexed Clinical Studies (188)

Patient Literacy & FDA Rules — Clinical Trials & Study Reports (188)

Page 2 of 7 • Sorted by Participant Sample Size (N)
Randomized Controlled Trial PMID 42982936

Randomized Controlled Trial: Resistance training and protein supplementation in patients with incurable gastroesophageal cancer

Resistance training combined with protein supplementation was not feasible during first-line chemotherapy in patients with incurable gastroesophageal cancer due to low accrual and low adherence to protein supplementation.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • 2026-11-05 Read Study
Randomized Controlled Trial PMID 42967746

Randomized Controlled Trial: Phytosterol-enriched corn and wheat germ blended oil improves lipid metabolism in hyperlipidemia via the AMPK/PPARα/CPT1 pathway

PCWGO effectively improved lipid metabolism in both humans and animal models and may have beneficial effects on oxidative status. Its hypolipidemic effects may be related to activation of the AMPK/PPARα/CPT1 pathway, promoting fatty acid β-oxidation.

Food research international (Ottawa, Ont.) • 2026-10-24 Read Study
Phase 3 Randomized Trial PMID 41297629

Can This Approach Help? Inside the Latest Research on How the body absorbs the medicine and how the medicine works in the body of

Single dose AQST-109 demonstrated PK exposures consistently bracketed within established levels for approved intramuscular epinephrine and autoinjectors, with a more rapid time-to-maximum plasma concentration and comparable PD...

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology • 2026-04-15 Read Study
Evidence Methodology, PubMed Verification & YMYL Standards

Frequently Asked Questions About dotMD Clinical Trial Breakdowns

Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.